Question 1

Q: What is Alzheimer’s Disease?

A: Alzheimer’s disease is a progressive neurodegenerative condition that affects a person’s memory and other cognitive functions, making it difficult to perform daily tasks and activities.

Question 2

Q: What is the difference between Alzheimer’s disease and dementia?

A: Dementia is a clinical syndrome of progressive cognitive impairment. The most common cause is Alzheimer’s disease. A neurologic evaluation is needed to determine the cause of dementia so that the most appropriate treatment can be provided.

Question 3

Q: What is the difference between dementia and Alzheimer’s disease?

A: Dementia is a general term for a group of memory disorders that can cause loss of memory, thinking abilities, language, problem-solving, and judgment skills. Alzheimer's is a specific medical disease and also a type of dementia.

Question 4

Q: What is Alzheimer’s?

A: There is no cure for Alzheimer's disease, but it can be managed with proper care.

Question 5

Q: What is typically the first sign of Alzheimer’s disease?

A: The first sign of Alzheimer’s disease is typically mild forgetfulness. A person may have trouble remembering recent events or take longer than before to finish a task.

Question 6

Q: What changes in the brain happen to people with Alzheimer’s disease?

A: Alzheimer’s disease is a degenerative brain disorder that leads to memory loss and cognitive decline. It is caused by the buildup of abnormal proteins in the brain, which leads to the death of nerve cells.

Question 7

Q: What is dementia?

A: Dementia is a loss of thinking, remembering, and reasoning skills that interferes with a person’s daily life and activities. Alzheimer’s disease is the most common cause of dementia among older people. Other causes of dementia include blood-vessel disease in the brain (called vascular dementia), Parkinson’s disease, frontotemporal dementia, and Lewy body disease.

Question 8

Q: What is a leaky blood-brain barrier?

A: The blood-brain barrier is a protective barrier that separates the brain from the bloodstream. When this barrier is damaged, it’s called a leaky brain.

Question 9

Q: What is Alzheimer’s disease and how does it differ from dementia?

A: Dementia is a general term for diseases that cause the gradual loss of ability to think, communicate, and live independently.

Question 10

Q: What is a placebo?

A: A placebo is an inactive pill, liquid or powder that has no treatment value.

Question 11

Q: What is Alzheimer's?

A: The exact cause of Alzheimer’s disease is still unknown, but researchers believe it may be related to abnormal deposits of proteins in the brain.

Question 12

Q: How does Alzheimer's usually progress?

A: Alzheimer's disease typically progresses slowly, beginning in a pre-symptomatic stage and advancing through several stages.

Question 13

Q: How is Alzheimer's treated?

A: There is no prevention, cure or approved disease-modifying intervention for Alzheimer’s disease.

Question 14

Q: What is early-onset Alzheimer's?

A: Early-onset Alzheimer's disease is when people under the age of 65 are diagnosed with Alzheimer's disease.

Question 15

Q: What are other types of dementia besides Alzheimer’s disease?

A: Alzheimer's disease is the most common type of dementia, but there are several other types as well. Vascular dementia is one of these other types, and it can sometimes occur after a stroke or brain injury. Symptoms of vascular dementia can include changes in thinking, memory, and behavior.

Question 16

Q: What are the Early Symptoms of Alzheimer’s?

A: The early symptoms of Alzheimer’s disease can include memory lapses, impaired thinking, speaking, reasoning, spatial issues, and judgement.

Question 17

Q: What are the Stages of Alzheimer’s Disease?

A: 1. Preclinical stage

2. Early stage

3. Middle stage

4. Late stage

Question 18

Q: What are the stages in the development of Alzheimer’s disease?

A: Alzheimer's disease is a progressive disease that causes cognitive decline and eventually leads to total care.

Question 19

Q: What are the different types of clinical trials?

A: Clinical trials are research studies that test how well new medical approaches work in people.

Question 20

Q: What are the phases of clinical trials?

A: Clinical trials are conducted in phases.

Question 21

Q: What is the function of the Alzheimer’s Research Association?

A: We are a non-profit that helps caregivers of dementia and Alzheimer’s disease.

Question 22

Q: What kinds of products and services does the Alzheimer’s Research Association offer?

A: The Alzheimer's Research Association offers easy-to-read E-books to help give you some of the most important information on handling the disease and the problems that it presents. The Association also has a complete store on-site for any and all products that would make the lives of caregivers, patients, and seniors in general easier.

Question 23

Q: What else does the Alzheimer’s Research Association do to help caregivers?

A: The Alzheimer's Research Association has gathered information on products and services that can help caregivers and patients of Alzheimer's disease. They have looked at the problems and found some of the best solutions by doing extensive research for the best the marketplace has to offer.

Question 24

Q: How is the safety of the participant protected?

A: Clinical trials are regulated by ethical and legal codes to protect participants, and an IRB reviews the clinical research plan to make sure people in the research study will be treated fairly and that any risks will be explained to them.

Question 25

Q: What is translational research and why is it an important part of Alzheimer’s disease research?

A: Translational research is important because it allows knowledge from the laboratory to be applied as quickly as possible to new clinical tests or interventions.

Question 26

Q: What is basic research and why is it an important part of Alzheimer’s disease research?

A: Basic biomedical research helps scientists understand how and why Alzheimer's disease starts and progresses. This research is essential for developing therapies to fight the disease.

Question 27

Q: What kind of research do we do?

A: We don't do research to find a cure, but we do research to help caregivers more effectively support their Alzheimer's patients.

Question 28

Q: Why is inflammation in the brain important?

A: Neuroinflammation is caused by microglia, which are the most common cells in our brains.

Question 29

Q: What type of long-term follow-up care is part of this study?

A: The experimental treatment being tested may be effective because it has been tested before and hospitalization may be required. However, reimbursement for other expenses is unclear. Results of the trials may be provided to the participant.

Question 30

Q: How is Alzheimer’s Diagnosed?

A: There is no one definitive test for diagnosing Alzheimer’s disease, but doctors can use a combination of physical exams, neuropsychological tests, and brain scanning to confirm the diagnosis with 90 percent accuracy.

Question 31

Q: How long do people live after getting diagnosed with Alzheimer’s?

A: The time from diagnosis of Alzheimer’s to the end of life varies. Life expectancy with Alzheimer’s can be as little as three years if the person is over 80 years old when diagnosed, or as long as ten years—or even longer—if the person is younger than 80 when diagnosed.

Question 32

Q: How is Alzheimer’s disease diagnosed?

A: There is no definitive way to diagnose Alzheimer's disease while a person is alive. The only way to definitively diagnose Alzheimer's disease is to find out whether there are plaques and tangles in brain tissue, which can only be done after a person dies.

Question 33

Q: How many people in the United States have Alzheimer’s disease?

A: Alzheimer's disease is a degenerative disease that affects the brain and nervous system. It is the most common form of dementia, and symptoms usually begin after age 60.

Question 34

Q: What causes Alzheimer’s disease?

A: The underlying cause of Alzheimer’s disease is not fully understood, but it is believed to be related to the loss of neurons and the accumulation of abnormal proteins in the brain.

Question 35

Q: What causes Alzheimer’s?

A: There is no single cause of Alzheimer’s disease. Instead, it is likely that a combination of genetic, lifestyle, and environmental factors contribute to the development of the disease.

Question 36

Q: What is mild cognitive impairment?

A: Mild cognitive impairment is a condition in which people have more memory problems than normal for their age, but their symptoms are not as severe as in Alzheimer’s disease.

Question 37

Q: How do you detect Alzheimer’s before it’s too late?

A: 1. Get a brain scan.
2. Take cognitive tests.

Question 38

Q: How do you reverse Alzheimer’s Disease and Cognitive Decline?

A: The Carroll Institute's Signature Programs page discusses our proprietary application of the Bredesen Protocol to see how we have created a step-by-step method of mentoring people through Alzheimer's reversal.

Question 39

Q: How do I know if I qualify for a clinical trial?

A: Alzheimer's disease is a progressive degenerative disease of the brain that is characterized by memory loss, difficulty with cognitive tasks, and eventual loss of all brain function. Early signs of Alzheimer's disease include memory problems and changes in mood or behavior.

Question 40

Q: What is clinical research?

A: Clinical research is a health-related research study in human beings that follows a pre-defined plan.

Question 41

Q: What is a clinical trial?

A: A clinical trial is a research study that follows a pre-defined protocol.

Question 42

Q: Why participate in a clinical trial?

A: Clinical trials are important, and you should consider participating in one if you are eligible.

Question 43

Q: What happens when a person signs up for a clinical trial?

A: If someone is interested in participating in a clinical trial at the UCSF Memory and Aging Center, her/his name will be added to our list of interested potential participants.

Question 44

Q: Who can participate in a clinical trial?

A: Clinical trials have guidelines about who can participate. The factors that allow someone to participate in a clinical trial are called inclusion criteria and those that disallow someone from participating are called exclusion criteria.

Question 45

Q: What happens during a trial?

A: Clinical trials are research studies in which new treatments – drugs, diagnostics, devices, and other therapies – are tested in people to see if they are safe and effective.

Question 46

Q: What are some common inclusion criteria for clinical trials for Alzheimer’s disease at UCSF?

A: .

Question 47

Q: What are some common exclusion criteria for clinical trials for AD at UCSF?

A: There are many reasons why someone might not be eligible for an Alzheimer's clinical trial, including not being stable on Alzheimer's medications, having another condition that could impact the results of the trial, or not being able to undergo an MRI scan.

Question 48

Q: Who pays for research?

A: The organization that is sponsoring the clinical research study pays for the study.

Question 49

Q: Where do the ideas for trials come from?

A: Clinical trials are ideas that come from researchers who want to test new therapies or procedures in the laboratory and in animal studies.

Question 50

Q: What should people consider before participating in a clinical trial?

A: The biggest benefit of participating in a clinical trial is the regular contact with the study team. These visits provide an opportunity to get state-of-the-art AD care and also to talk on an ongoing basis with experts in AD who have lots of practical experience and a broad perspective on the disease.

Question 51

Q: What are the benefits and risks of participating in a clinical trial?

A: 1. Gain access to new, potentially life-saving treatments
2. Help advance medical knowledge
3. Receive expert medical care at no cost

Question 52

Q: What should people consider before participating in a trial?

A: 1. What is the purpose of the clinical trial?
2. Who is sponsoring the clinical trial?
3. Who has reviewed and approved the clinical trial?
4. How long will the clinical trial last?
5. What are the risks and benefits of participating in the clinical trial?
6. What are the side effects of the treatment being tested in the clinical trial?
7. What are the possible outcomes of the clinical trial?
8. What are the costs

url / atext / target url
https://www.gadaalliance.org/women/ study ↳https://academic.oup.com/ageing/article/doi/10.1093/ageing/afw208/2631398/Inequalities-in-	www.gadaalliance.org
https://dementiaresources.org.au/ abstract ↳https://academic.oup.com/gerontologist/article-abstract/57/5/e94/2852108/Implementing-Mont	dementiaresources.org.au
https://www.medicalnewstoday.com/articles/317028.php?sr findings ↳https://academic.oup.com/brain/article/3737867/Repurposed-drugs-targeting-eIF2-P-mediated?	www.medicalnewstoday.com
http://www.bbc.com/news/health-39641123 published in the journal brain ↳https://academic.oup.com/brain/article/doi/10.1093/brain/awx074/3737867/Repurposed-drugs-t	www.bbc.com
https://academic.oup.com/brain/issue/137/1 mechanisms of deep brain stimulation for essential tremor ↳https://academic.oup.com/brain/article/137/1/4/365249
https://academic.oup.com/brain/issue/137/1 the role of the posterior cingulate cortex in cognition and disease ↳https://academic.oup.com/brain/article/137/1/12/358120
https://academic.oup.com/brain/issue/137/1 pantethine treatment is effective in recovering the disease phenotype induced by ketogenic diet in a pantothenate ↳https://academic.oup.com/brain/article/137/1/57/364822
https://academic.oup.com/brain/issue/137/1 brain volumes predict neurodevelopment in adolescents after surgery for congenital heart disease ↳https://academic.oup.com/brain/article/137/1/268/364129
https://academic.oup.com/brain/issue/137/1 abnormal autonomic and associated brain activities during rest in autism spectrum disorder ↳https://academic.oup.com/brain/article/137/1/153/359739
https://academic.oup.com/brain/issue/137/1 disrupted brain network topology in parkinson s disease a longitudinal magnetoencephalography study ↳https://academic.oup.com/brain/article/137/1/197/363204

title / url	PR	relevance	links	rel links	external links	external domains	referring domains	external backlinks
Volume 137 Issue 1 \| Brain \| Oxford Academic https://academic.oup.com/brain/issue/137/1	0.28	0.59	272	47	30	2	0	0
Search Results \| Brain \| Oxford Academic https://academic.oup.com/brain/search-results?f_SemanticFilterTopics=clinical%20diagnosis	0.28	0.67	218	40	21	2	0	0
CLINICAL AND PATHOLOGICAL FEATURES OF DIFFUSE CORTICAL LEWY BODY DISEASE (LEWY BODY DEMENTIA) \| Brain \| Oxford Academic https://academic.oup.com/brain/article-abstract/110/5/1131/281586?redirectedFrom=fulltext	0.28	0.81	107	25	3	3	0	0
Progression marker of Parkinsonu2019s disease: a 4-year multi-site imaging study \| Brain \| Oxford Academic https://academic.oup.com/brain/article/140/8/2183/4032257	0.28	0.8	207	17	4	4	1	1
Volume 140 Issue 5 \| Brain \| Oxford Academic https://academic.oup.com/brain/issue/140/5	0.28	0.86	340	61	40	2	0	0
Parkinson's disease, insulin resistance and novel agents of neuroprotection \| Brain \| Oxford Academic https://academic.oup.com/brain/article/136/2/374/287025	0.28	0.78	512	16	4	3	0	0
Volume 138 Issue 6 \| Brain \| Oxford Academic https://academic.oup.com/brain/issue/138/6	0.28	0.71	326	60	41	2	0	0
Hygiene and the world distribution of Alzheimeru2019s disease \| Evolution, Medicine, and Public Health \| Oxford Academic https://academic.oup.com/emph/article/2013/1/173/1861845	0.28	0.89	353	6	2	1	1	1
topography of grey matter involvement in early and late onset Alzheimer's disease \| Brain \| Oxford Academic https://academic.oup.com/brain/article/130/3/720/279947	0.23	0.93	310	19	4	4	0	0
Volume 138 Issue 5 \| Brain \| Oxford Academic https://academic.oup.com/brain/issue/138/5	0.21	0.92	341	62	41	2	0	0

title / url	PR	relevance	links	rel links	external links	external domains	referring domains	external backlinks
Progression marker of Parkinsonu2019s disease: a 4-year multi-site imaging study \| Brain \| Oxford Academic https://academic.oup.com/brain/article/140/8/2183/4032257	0.28	0.8	207	17	4	4	1	1
topography of grey matter involvement in early and late onset Alzheimer's disease \| Brain \| Oxford Academic https://academic.oup.com/brain/article/130/3/720/279947	0.23	0.93	310	19	4	4	0	0
MalaCards: an amalgamated human disease compendium with diverse clinical and genetic annotation and structured search \| Nucleic Acids https://academic.oup.com/nar/article/45/D1/D877/2572056?keytype=ref&ijkey=3W1Wb7TCY0KBKbg	0.21	0.96	214	9	7	7	1	1

domain	count	semantic flow ^™
http://alz.org/	11	0.61	alz.org
http://medicalnewstoday.com/	7	0.39	medicalnewstoday.com
http://wikipedia.org/	6	0.17	wikipedia.org
http://omim.org/	2	0.1	omim.org
http://aldf.com/	1	0.09	aldf.com
http://healthcanal.com/	1	0.08	healthcanal.com
http://brainsfordementiaresearch.co.uk/	2	0.08	brainsfordementiaresearch.co.uk
http://alzheimers.net/	1	0.08	alzheimers.net
http://healthline.com/	1	0.08	healthline.com
http://theconversation.com/	1	0.08	theconversation.com

domain	count	semantic flow ^™
http://doi.org/	1843	102.37	doi.org
http://nih.gov/	139	5.59	nih.gov
http://hhs.gov/	6	0.33	hhs.gov
http://alz.org/	5	0.17	alz.org
http://cdc.gov/	4	0.13	cdc.gov
http://ucla.edu/	2	0.13	ucla.edu
http://lymebook.com/	2	0.1	lymebook.com
http://restormedicine.com/	2	0.1	restormedicine.com
http://fda.gov/	1	0.08	fda.gov
http://orphadata.org/	1	0.08	orphadata.org

Oup.com / Alzheimers disease

Popular pages pointing to oup.com

Popular pages from oup.com

Popular prospect pages from oup.com

Domains with most semantic flow to oup.com

Domains with most semantic flow from oup.com

Most linked pages from oup.com

Hubs from oup.com

Similar domains to oup.com

Random 'alzheimers disease FAQs', may be related to more specific topics, not general alzheimers disease topic.

ALZHEIMERS DISEASE FAQs

END-STAGE KIDNEY DISEASE AND ALZHEIMER'S DISEASE/DEMENTIA?.

ALZHEIMER'S: PROGRESSION, TREATMENT, AND EARLY-ONSET EXPLANATION.

WHAT ARE THE

DOES THE ALZHEIMER’S RESEARCH ASSOCIATION

IMPORTANCE OF TRANSLATIONAL RESEARCH IN ALZHEIMER'S DISEASE.

DIAGNOSED AND ITS IMPACT IN THE US?.

ALZHEIMER'S DISEASE?.

DETECT AND REVERSE ALZHEIMER'S AND COGNITIVE DECLINE?.

UNDERSTANDING CLINICAL TRIALS: QUALIFICATION AND PARTICIPATION.

CRITERIA FOR CLINICAL TRIALS FOR

TRIAL?.

url	count	PR	score	semantic flow ^™	relevance	on topic	links	rel links	external links	external domains	referring domains	external backlinks
https://academic.oup.com/brain/search-results?q=&tax=brainj/1070	5	0.19	0.97	0.06	-1	no	-1	-1	-1	-1	0	0
https://academic.oup.com/brain/search-results?q=&tax=brainj/1010	5	0.19	0.96	0.06	0.91	yes	217	42	21	2	0	0
https://academic.oup.com/brain/pages/About	5	0.19	0.95	0.06	-1	no	-1	-1	-1	-1	0	0
https://academic.oup.com/brain/pages/Terms_and_Conditions	5	0.19	0.75	0.05	-1	-	-1	-1	-1	-1	0	0
https://academic.oup.com/brain/article/135/12/3735/286376	1	0.16	0.93	0.06	-1	no	-1	-1	-1	-1	0	0
https://academic.oup.com/brain/article/137/2/537/283818	1	0.16	0.94	0.06	0.89	yes	244	21	4	3	0	0
https://academic.oup.com/brain/article/138/8/2399/330664	1	0.16	0.91	0.06	-1	no	-1	-1	-1	-1	0	0
https://academic.oup.com/brain/article/134/7/2044/293996	1	0.16	0.85	0.06	0.59	yes	352	21	3	3	0	0
https://academic.oup.com/brain/article/139/3/891/2468754	1	0.15	0.91	0.06	0.95	yes	292	19	4	3	1	1
https://academic.oup.com/brain/issue/139/3	1	0.16	0.84	0.06	0.97	yes	341	69	44	2	0	0